Jianjun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianjun Chen has a total of 375 co-authors. Here are the top co-authors by number of shared publications:
Yichang Ren
Southern Medical University
32 shared publicationsLing Li
Sun Yat Sen University
30 shared publicationsJin Liu
Key Laboratory of Tropical Biological Resources of Ministry of Education and One Health Institute, School of Pharmaceutical Sciences
29 shared publicationsBinbin Cheng
21 shared publicationsXiaopeng Peng
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Jiangxi Provincal Key Laboratory of Tissue Engineering, School of Pharmacy
21 shared publicationsZichao Yang
Southern Medical University
19 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Hydrophobic Tagging Enables Targeted Degradation of the Membrane Protein TIM-3
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising and potential target for cancer immunotherapy; however, antibodies targeting TIM-3 currently face issues such as limited efficacy. The development of small molecule inhibitors of TIM-3 is still in its early stages, and degraders targeting TIM-3 remain unexplored. To address this gap, we herein report the first design and synthesis of a series of hydrophobic tagging (HyT)-based TIM-3 degraders with immunomodulatory effects, utilizing a biologically inactive TIM-3 binder as the target protein ligand. Among them, compound ZQ7 exhibited a potent dose- and time-dependent TIM-3 degradation effect in vitro, with a DC50 of 8.57 μM and a Dmax of 78%. Mechanistic studies suggested that ZQ7 promotes the degradation of TIM-3 through the ubiquitin-proteasome system upon internalization of the target protein. In addition, ZQ7 effectively reduced TIM-3 expression in tumor tissues and activated the tumor immune microenvironment, thereby significantly inhibiting tumor growth in vivo. In summary, ZQ7, as a novel TIM-3 degrader, merits further investigation. Furthermore, our study offers a feasible strategy that can transform biologically inactive chemical entities into bioactive molecules, providing a proof of concept for revitalizing inactive ligands.
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHydrophobic Tagging Enables Targeted Degradation of the Membrane Protein TIM-3
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a promising and potential target for cancer immunotherapy; however, antibodies targeting TIM-3 currently face issues such as limited efficacy. The development of small molecule inhibitors of TIM-3 is still in its early stages, and degraders targeting TIM-3 remain unexplored. To address this gap, we herein report the first design and synthesis of a series of hydrophobic tagging (HyT)-based TIM-3 degraders with immunomodulatory effects, utilizing a biologically inactive TIM-3 binder as the target protein ligand. Among them, compound ZQ7 exhibited a potent dose- and time-dependent TIM-3 degradation effect in vitro, with a DC50 of 8.57 μM and a Dmax of 78%. Mechanistic studies suggested that ZQ7 promotes the degradation of TIM-3 through the ubiquitin-proteasome system upon internalization of the target protein. In addition, ZQ7 effectively reduced TIM-3 expression in tumor tissues and activated the tumor immune microenvironment, thereby significantly inhibiting tumor growth in vivo. In summary, ZQ7, as a novel TIM-3 degrader, merits further investigation. Furthermore, our study offers a feasible strategy that can transform biologically inactive chemical entities into bioactive molecules, providing a proof of concept for revitalizing inactive ligands.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4406-4429
Discovery of Aurora A/HDAC dual-target inhibitors: broad-spectrum in vitro antitumor activity and in vivo pharmacokinetic limitations
This study aimed to develop dual-target inhibitors against Aurora A and HDACs, and identified Z20 as the optimal candidate via in vitro screening.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4406-4429
Discovery of Aurora A/HDAC dual-target inhibitors: broad-spectrum in vitro antitumor activity and in vivo pharmacokinetic limitations
This study aimed to develop dual-target inhibitors against Aurora A and HDACs, and identified Z20 as the optimal candidate via in vitro screening.
- 20 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20570-20595
Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity
Programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) represents a critical immune checkpoint in cancer immunotherapy; however, most small-molecule PD-1/PD-L1 inhibitors suffer from poor aqueous solubility. Here, we designed a series of quaternary ammonium-based PD-1/PD-L1 inhibitors. Among them, QA9 exhibited potent PD-1/PD-L1 inhibition (IC50 = 18.7 nM), outperforming the lead compound NP19, and demonstrated a 600-fold improvement in water solubility (0.642 vs 0.001 mg/mL). X-ray crystallography revealed that QA9 stabilizes the PD-L1 dimer through multiple interactions, providing a structural basis for its high affinity. In MC38/Jurkat and HCT116/Jurkat coculture models, QA9 enhanced immune-mediated tumor cell death. Additionally, QA9 suppressed VEGF-A-induced tube formation and migration in HUVECs, which was associated with reduced FAK phosphorylation. Furthermore, in an MC38 mouse colon cancer model, QA9 showed robust antitumor activity without overt toxicity. Collectively, the quaternary ammonium strategy represents an effective approach to developing water-soluble PD-1/PD-L1 inhibitors with dual immunomodulatory and antiangiogenic functions.
- 20 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20570-20595
Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity
Programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) represents a critical immune checkpoint in cancer immunotherapy; however, most small-molecule PD-1/PD-L1 inhibitors suffer from poor aqueous solubility. Here, we designed a series of quaternary ammonium-based PD-1/PD-L1 inhibitors. Among them, QA9 exhibited potent PD-1/PD-L1 inhibition (IC50 = 18.7 nM), outperforming the lead compound NP19, and demonstrated a 600-fold improvement in water solubility (0.642 vs 0.001 mg/mL). X-ray crystallography revealed that QA9 stabilizes the PD-L1 dimer through multiple interactions, providing a structural basis for its high affinity. In MC38/Jurkat and HCT116/Jurkat coculture models, QA9 enhanced immune-mediated tumor cell death. Additionally, QA9 suppressed VEGF-A-induced tube formation and migration in HUVECs, which was associated with reduced FAK phosphorylation. Furthermore, in an MC38 mouse colon cancer model, QA9 showed robust antitumor activity without overt toxicity. Collectively, the quaternary ammonium strategy represents an effective approach to developing water-soluble PD-1/PD-L1 inhibitors with dual immunomodulatory and antiangiogenic functions.
- Open Access
- 8 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 6831-6851
Discovery of a small molecule RIOK1 inhibitor CINS-1 against colorectal cancer via disrupting ribosomal biosynthesis
- 8 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 6831-6851
Open AccessDiscovery of a small molecule RIOK1 inhibitor CINS-1 against colorectal cancer via disrupting ribosomal biosynthesis
- Open Access
- 11 March 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Selective GLUT9 inhibitors for hyperuricemia via intestinal mechanism
- 11 March 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessSelective GLUT9 inhibitors for hyperuricemia via intestinal mechanism
- 8 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6546-6568
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy
- 8 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6546-6568
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy
- Open Access
- 18 February 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 63
Exogenous Epstein–Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy
Immune checkpoint blockade (ICB) therapy continues to face limitations due to tumor resistance linked to suppressed interferon (IFN) signaling. This suppression can be attributed to multiple mechanisms, among which viral pathogens represent a compelling though not yet fully elucidated factor. Here, we demonstrate that exogenous Epstein–Barr virus-encoded EBNA1 drives immunosuppression via enhanced RNA-editing enzyme ADAR1-mediated RNA editing. Comparative tumor model analyses revealed that EBNA1 overexpression reduced CD8 + T-cell infiltration, inhibited IFN responses, polarized macrophages toward the M2 phenotype, and accelerated tumor growth. Mechanistically, EBNA1 forms a trimeric complex with insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) and eukaryotic translation initiation factor 4G1 (EIF4G1), enhancing ADAR1 translation. Elevated ADAR1 further increased A-to-I editing of dsRNA, particularly within SINE elements near IFN-associated genes. This editing masked immunostimulatory signals, impairing RNA sensor activation and blunting IFN pathways. Notably, combining the EBNA1-targeting PROTAC degrader EP-1215 with anti-PD-1 effectively restored IFN signaling, enhanced T-cell infiltration, and suppressed EBNA1 + tumors in humanized mice. This viral exploitation of RNA editing suggests that targeting EBNA1 could be a strategy to convert “cold” tumors into “hot” targets amenable to ICB therapy.
- 18 February 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 63
Open AccessExogenous Epstein–Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy
Immune checkpoint blockade (ICB) therapy continues to face limitations due to tumor resistance linked to suppressed interferon (IFN) signaling. This suppression can be attributed to multiple mechanisms, among which viral pathogens represent a compelling though not yet fully elucidated factor. Here, we demonstrate that exogenous Epstein–Barr virus-encoded EBNA1 drives immunosuppression via enhanced RNA-editing enzyme ADAR1-mediated RNA editing. Comparative tumor model analyses revealed that EBNA1 overexpression reduced CD8 + T-cell infiltration, inhibited IFN responses, polarized macrophages toward the M2 phenotype, and accelerated tumor growth. Mechanistically, EBNA1 forms a trimeric complex with insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) and eukaryotic translation initiation factor 4G1 (EIF4G1), enhancing ADAR1 translation. Elevated ADAR1 further increased A-to-I editing of dsRNA, particularly within SINE elements near IFN-associated genes. This editing masked immunostimulatory signals, impairing RNA sensor activation and blunting IFN pathways. Notably, combining the EBNA1-targeting PROTAC degrader EP-1215 with anti-PD-1 effectively restored IFN signaling, enhanced T-cell infiltration, and suppressed EBNA1 + tumors in humanized mice. This viral exploitation of RNA editing suggests that targeting EBNA1 could be a strategy to convert “cold” tumors into “hot” targets amenable to ICB therapy.
- Open Access
- 22 January 2026
- Vol. 21 (1)
Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1
Molecular glues (MGs), a class of small-molecule degraders, exhibit drug-like properties that generally conform to Lipinski's rule of five, while uniquely mediating the stabilization or induction of protein-protein interactions. By altering the surface properties of either target proteins or E3 ligases, MGs promote the formation of a ternary complex comprising the MG, an E3 ligase, and a target protein. This interaction facilitates the polyubiquitination and subsequent degradation of the target protein via the ubiquitin-proteasome system. Owing to its distinctive mechanism of action and broad therapeutic potential, MG is offering novel approaches to disease treatment. This review summarizes recent advances in MGs targeting NIMA-related kinase 7 (NEK7), WEE1, CDK2, GSPT1 and VAV1, emphasizing the rational design, benefits, and potential limitations, highlighting rational design principles, advantages, and current limitations including challenges in achieving selectivity and rational design that provide critical insights for enhancing MG efficacy. These developments are crucial for advancing the application and optimization of molecular glues targeting NEK7, WEE1, CDK2, GSPT1 and VAV1.
- 22 January 2026
- Vol. 21 (1)
Open AccessAdvances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1
Molecular glues (MGs), a class of small-molecule degraders, exhibit drug-like properties that generally conform to Lipinski's rule of five, while uniquely mediating the stabilization or induction of protein-protein interactions. By altering the surface properties of either target proteins or E3 ligases, MGs promote the formation of a ternary complex comprising the MG, an E3 ligase, and a target protein. This interaction facilitates the polyubiquitination and subsequent degradation of the target protein via the ubiquitin-proteasome system. Owing to its distinctive mechanism of action and broad therapeutic potential, MG is offering novel approaches to disease treatment. This review summarizes recent advances in MGs targeting NIMA-related kinase 7 (NEK7), WEE1, CDK2, GSPT1 and VAV1, emphasizing the rational design, benefits, and potential limitations, highlighting rational design principles, advantages, and current limitations including challenges in achieving selectivity and rational design that provide critical insights for enhancing MG efficacy. These developments are crucial for advancing the application and optimization of molecular glues targeting NEK7, WEE1, CDK2, GSPT1 and VAV1.
- 22 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 306, 118605
Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity
- 22 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 306, 118605
Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity